Non-interventional study consisting of a population of patients who had received for soft tissue sarcoma by at least 2 courses of Yondelis® at a dose of 1.5 mg / m² / 3 weeks after failure or intolerance to doxorubicin / ifosfamide from 2007 to 2011.
Patient selection is based on a database of retrospectively within the GSF / GETO. The tumor assessment must be made by scanner at baseline and post-C2 or C3 and should be available and sent to sponsor. The comparative reading of the imaging is centralized and made without the knowledge of the local assessment: * sum of the large diameter for 2 imagery (baseline and 1st evaluation * tumor density on areas of interest for the 2 imaging (baseline and 1st evaluation * Rank patients according to two methods (Choi and RECIST): complete response, partial response, stability, progress and non-assessable.
Study Type
OBSERVATIONAL
Enrollment
134
Bergonie Institute
Bordeaux, France
Oscar Lambret Center
Lille, France
Antoine Lacassagne Center
Nice, France
Curie Institute
Paris, France
To assess the feasibility of tumor response according to CHOI criteria
percentage of cases with a feasible evaluation according to CHOI
Time frame: after 6 weeks of treatment
To classify patients into two categories (progression or no progression) according to RECIST and to CHOI
percentage of cases with a feasible evaluation according to RECIST
Time frame: after 6 weeks of treatment
To determine percentage of false progression
define as patient progressing according to RECIST and not progressing according to CHOI number of patient in each categories, according to each method of measurement
Time frame: after 6 weeks of treatment
To determine predictive values of progression free survival and overall survival
progression free survival = median time between date of inclusion and date of clinical or radiological progression overall survival = median time between date of inclusion and date of death
Time frame: after 6 weeks of treatment
To characterize the profile of patients in false progression
patient in progression according to RECIST but not progressing according to CHOI
Time frame: after 6 weeks of treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Henri Becquerel Center
Rouen, France
Cancer Institute of the West
Saint-Herblain, France